Reformatting historical data and getting scientists to agree on how to generate it are among the biggest hurdles in hybrid ...

Autolomous CEO Alexander Seyf explains why collaboration, not competition, could unlock progress in cell and gene therapy ...

From scale-up pitfalls to tech transfer nightmares, learn how emerging biotech companies can avoid costly mistakes when ...

Bio-Techne's new Bristol facility strengthens its cell therapy supply chain with GMP small molecule production, complementing ...

Learn strategies for controlling trace metals, polysorbate degradation, and other key formulation risks that can compromise ...